The transfer of fecal microbiota from cancer patients who exhibited a positive response to ICIs into germ-free mice or mice treated with broad-spectrum antibiotics has enhanced the anti-tumor efficacy of anti-PD-1. This evidence concerns the gene PDCD1 and neoplasm.